Document is current
Any future updates will be listed below
-
Authors
Dámaso, Estela
Canet-Hermida, Júlia
Vargas-Parra, Gardenia
Velasco, Àngela
Marín, Fátima
Darder, Esther
del Valle, Jesús
Fernández, Anna
Izquierdo, Àngel
Mateu, Gemma
Oliveras, Glòria
Escribano, Carmen
Piñol, Virgínia
Uchima, Hugo-Ikuo
Soto, José Luis
Hitchins, Megan
Farrés, Ramon
Lázaro, Conxi
Queralt, Bernat
Brunet, Joan
Capellá, Gabriel https://orcid.org/0000-0002-4669-7320
Pineda, Marta
-
Funding
Funding for this research was provided by:
Spanish Ministry of Economy and Competitiveness cofunded by FEDER funds (SAF2015-68016-R and SAF2012-33636)
CIBERONC
Spanish Association Against Cancer (080253)
Government of Catalonia (2014SGR338)
Government of Catalonia (2017SGR1282, PERIS SLT002/16/0037)
The Mexican National Council for Science and Technology (CONACyT) fellowship
Catalonia Health Department (SLT002/16/00409)
CERCA Generalitat de Catalunya
- License Information
-
More Information
Article History
Received: 23 May 2019
Accepted: 9 October 2019
First Online: 28 November 2019
Competing interest
: GC and JdV have received personal fees from VCN Biosciences and AstraZeneca, respectively, outside the submitted work. There are no other relationships or activities that could appear to have influenced the submitted work. All other authors declare that they have no competing interest.
: This study was approved by the Ethics Committee of the Institut d’Investigació Biomèdica de Bellvitge (IDIBELL). <i>S</i>pecimens were obtained after the patients had provided written informed consent.
: We obtained written informed consent from the patient to publish patient’s clinical and molecular information.
